Shayna Sarosiek, MD, at #ASH23 discusses an ongoing clinical trial at Dana-Farber that uses rituximab and acalabrutinib to treat anti-MAG neuropathy, which occurs in some patients with IgM #MGUS or #Waldenstrom macroglobulinemia.
At ash. I presented an abstract on preliminary data in our trial using riTUXimab and a caliber for patients who have anti mag neuropathy. So a lot of patients with IgM um monoclonal gammopathy have a neuropathy and the neuropathy if it progresses can become quite symptomatic and affect a patient's quality of life and functional status and neuropathy in many patients with an IgM gammopathy is related to something called anti meg antibodies. And we don't know what is the clear treatment are the right treatment for those patients to use. So we're studying that in this trial and we're also looking at what's the best way to follow neuropathy in our patients. And in those patients, we're seeing some stability and improvement on multiple different scales. And this is preliminary data with the first eight patients in the trial. But we're really encouraged by the data and looking forward to what we can learn about improving treatment for these patients with anti mag neuropathy.
